Despite the threat of Omicron looming large, some pharma companies such as Aurobindo Pharma, Lupin and Biocon are likely to move out of large-cap to mid-cap.
According an ICICI Securities research, bi-annual reclassification of stocks based on their market capitalisation by the Association of Mutual Funds in India, will see some of the major pharma companies and bank stocks being downgraded from large- to mid-cap.
